Cilnidipine (FRC-8653) is a dihydropyridine (DHP) type of calcium channel antagonist
originally developed in Japan. Unlike other calcium channel antagonists, cilnidipine blocks …

Cilnidipine is a unique Ca2+ channel blocker with an inhibitory action on the sympathetic N‐
type Ca2+ channels, which is used for patients with hypertension in Japan. Cilnidipine has …

Hypertension is one of the most common conditions seen in primary care and a major public
health problem in India. It can lead to various complications if not detected early and treated …

Several classes of antihypertensive agents have been in clinical use, including diuretics, α-
blockers, β-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II type 1 …

Preventing the development of cardiovascular problems is a key objective of
antihypertensive drugs. Many of the non-pressure related coronary risk factors for …

Introduction: Hypertension is one of the most common cardiovascular diseases, and the
prevalence of hypertension continues to rise across the globe. National and international …

Cilnidipine is a novel and unique 1, 4-dydropyridine derivative calcium antagonist that
exerts potent inhibitory actions not only on L-type but also on N-type voltage-dependent …

Cardiac effects of L/N-type Ca2+ channel blocker cilnidipine were assessed using the
halothane-anesthetized canine model. Cilnidipine (1 and 3 μg/kg, iv) lowered the mean …

We compared the effects of cilnidipine and nifedipine retard on 24-h blood pressure (BP),
heart rate (HR), and autonomic nerve activity in patients with essential hypertension …

Cilnidipine is a novel dihydropyridine (DHP) antagonist. However, its pharmacological
effects on vascular DHP-sensitive L-type channels and protein kinase C (PKC)-mediated …